{
  "id": 15631798,
  "title": "2 High-Flying Dividend Stocks to Buy and Hold for a Decade",
  "url": "https://urgent.news/2026/10/19/2-high-flying-dividend-stocks-to-buy-and-hold-for-a-decade",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-19T17:15:01.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/10/19/2-high-flying-dividend-stocks-to-buy-and-hold-for-a-decade/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "Two healthcare companies, Merck (MRK) and AbbVie (ABBV), have outperformed the broader market this year, making them strong long-term investment options. Merck's shares have risen 39%, while AbbVie's have gained 24%, compared to the S&P 500's 12% increase year-to-date. Both companies demonstrate robust earnings growth and attractive dividend programs.\n\nMerck's Keytruda franchise posted $8.4 billion in sales, up 5% year-over-year, while its HPV vaccines, Gardasil and Gardasil 9, increased revenue by 4% to $1.2 billion. The company is set to lose patent exclusivity for Keytruda by 2028, but the newer Keytruda Qlex, a subcutaneous version, could help retain market share. Merck has also approved newer products, such as Winrevair for pulmonary arterial hypertension, and has a promising pipeline, including a personalized cancer vaccine with Moderna.\n\nAbbVie's second-quarter revenue grew 10.2% year-over-year to almost $17 billion, with adjusted EPS rising 22.9% to $3.65. Its core growth drivers, Skyrizi and Rinvoq, are performing well, with sales growing by about 24% year-over-year. AbbVie's pipeline includes promising candidates like zumilokibart for eczema and ABBV-295, an investigational long-acting anti-obesity medicine. The company boasts a 54-year streak of consecutive dividend increases, making it a Dividend King, a rare achievement that ensures its commitment to returning value to shareholders.",
  "summary": "They may just be getting started.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 3,
    "also_reported_by": [
      {
        "outlet": "Motley Fool",
        "title": "2 \"Magnificent Seven\" Stocks to Buy and Hold for the Rest of the Decade",
        "url": "https://urgent.news/2026/10/19/2-magnificent-seven-stocks-to-buy-and-hold-for-the-rest-of-the-decade",
        "published": "2026-10-19T16:00:00.000Z"
      },
      {
        "outlet": "Nasdaq Markets",
        "title": "2 \"Magnificent Seven\" Stocks to Buy and Hold for the Rest of the Decade",
        "url": "https://urgent.news/2026/10/19/2-magnificent-seven-stocks-to-buy-and-hold-for-the-rest-of-the-decade-15625506",
        "published": "2026-10-19T16:20:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}